Articles with "line systemic" as a keyword



Photo by rgaleriacom from unsplash

Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study

Sign Up to like & get
recommendations!
Published in 2022 at "European Journal of Haematology"

DOI: 10.1111/ejh.13769

Abstract: This retrospective chart review examined real‐world healthcare resource utilization (HRU) in patients with AML ineligible for intensive therapy who received first‐line systemic therapy or best supportive care (BSC). read more here.

Keywords: best supportive; line systemic; ineligible intensive; first line ... See more keywords
Photo from wikipedia

Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Sign Up to like & get
recommendations!
Published in 2023 at "Journal of gastroenterology and hepatology"

DOI: 10.1111/jgh.16225

Abstract: BACKGROUND AND AIM The study goal was to compare the outcomes of patients with unresectable hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) as either first- or later-line systemic therapy. METHODS A total of… read more here.

Keywords: later line; line systemic; first line; therapy ... See more keywords
Photo by nci from unsplash

Predictors of first line systemic therapy for metastatic renal cell carcinoma in IMDC favorable risk patients.

Sign Up to like & get
recommendations!
Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.15_suppl.e17086

Abstract: e17086Background: With the induction of molecular targeted agents, which interfere with proteins that play critical roles in tumor growth and progression, and immune checkpoint inhibitors (ICI), th... read more here.

Keywords: predictors first; therapy metastatic; first line; systemic therapy ... See more keywords
Photo from wikipedia

The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis

Sign Up to like & get
recommendations!
Published in 2021 at "Frontiers in Immunology"

DOI: 10.3389/fimmu.2021.719650

Abstract: Background The optimal second-line systemic treatment model for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains controversial. A Bayesian network meta-analysis (NMA) was performed to address this issue with regard to… read more here.

Keywords: line; line systemic; treatment; optimal second ... See more keywords
Photo from wikipedia

Management of Hepatocellular Carcinoma after Progression on First-Line Systemic Treatment: Defining the Optimal Sequencing Strategy in Second Line and Beyond.

Sign Up to like & get
recommendations!
Published in 2020 at "Current oncology"

DOI: 10.3747/co.27.7103

Abstract: Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. It has a high mortality rate, especially when localized treatments fail. For about a decade, the only systemic treatment shown to improve… read more here.

Keywords: systemic treatment; hepatocellular carcinoma; line; line systemic ... See more keywords
Photo from wikipedia

Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

Sign Up to like & get
recommendations!
Published in 2021 at "World Journal of Gastroenterology"

DOI: 10.3748/wjg.v27.i19.2415

Abstract: BACKGROUND The majority of clinical trials of first-line systemic treatments for hepatocellular carcinoma (HCC) used placebo or sorafenib as comparators, and there are limited data providing a cross comparison of treatments in this setting, especially… read more here.

Keywords: hepatocellular carcinoma; bevacizumab; randomized controlled; line ... See more keywords